Upper Gastrointestinal Surgery, Department of Molecular medicine and Surgery, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden.
Cancer and Translational Medicine Research Unit, Medical Research Center, University of Oulu and Oulu University Hospital, Oulu, Finland.
Int J Cancer. 2019 Mar 15;144(6):1284-1291. doi: 10.1002/ijc.31840. Epub 2018 Oct 31.
Some investigations suggest a better prognosis in women compared to men with esophageal cancer but these differences are uncertain. The aim of our study was to clarify whether sex influences the prognosis after esophagectomy for esophageal squamous cell carcinoma and esophageal adenocarcinoma. A population-based and nationwide cohort study included almost all patients who underwent esophagectomy for esophageal cancer in Sweden in 1987-2010, with follow-up until 2016. Patients' sex was analyzed in relation to risk of mortality. Multivariable Cox regression provided hazard ratios (HR) with 95% confidence intervals (CI), adjusted for calendar period, age, education, comorbidity, tumor stage, neoadjuvant therapy, and surgeon volume. Among 1,816 participants, 1,024 (56%) had esophageal squamous cell carcinoma (355 [35%] women), and 792 (44%) had esophageal adenocarcinoma (103 [13%] women). Compared to men, women had a decreased overall all-cause mortality in esophageal squamous cell carcinoma (HR = 0.73, 95% CI 0.63-0.85). Stratified analyses showed decreased mortality limited to women aged >55 years (HR = 0.71, 95% CI 0.61-0.83), but in all tumor stages, particularly stages 0-I (HR = 0.54, 95% CI 0.37-0.79). Women also had decreased 90-day all-cause mortality, 5-year all-cause mortality, and 5-year disease-specific mortality in esophageal squamous cell carcinoma compared to men. For esophageal adenocarcinoma, no sex differences were found for any of the mortality outcomes. Thus, women who undergo esophagectomy for esophageal squamous cell carcinoma seem to have better prognosis than men, especially those with early tumor stages, whereas no sex differences in prognosis were found for esophageal adenocarcinoma.
一些研究表明,与男性食管癌患者相比,女性食管癌患者的预后更好,但这些差异并不确定。我们的研究旨在阐明性别是否会影响接受食管癌根治性切除术的患者的预后,这些患者的食管癌为食管鳞状细胞癌和食管腺癌。本研究采用基于人群和全国性队列研究,纳入了 1987 年至 2010 年期间在瑞典接受食管癌根治性切除术的几乎所有患者,随访至 2016 年。分析了患者的性别与死亡率之间的关系。多变量 Cox 回归分析提供了风险比(HR)及其 95%置信区间(CI),校正了日历时间、年龄、教育程度、合并症、肿瘤分期、新辅助治疗和外科医生手术量。在 1816 名参与者中,1024 名(56%)患有食管鳞状细胞癌(355 名女性,35%),792 名(44%)患有食管腺癌(103 名女性,13%)。与男性相比,女性患有食管鳞状细胞癌的总全因死亡率降低(HR=0.73,95%CI 0.63-0.85)。分层分析显示,死亡率的降低仅限于年龄>55 岁的女性(HR=0.71,95%CI 0.61-0.83),但在所有肿瘤分期中,尤其是 0-1 期(HR=0.54,95%CI 0.37-0.79)。与男性相比,女性患有食管鳞状细胞癌的 90 天全因死亡率、5 年全因死亡率和 5 年疾病特异性死亡率也较低。对于食管腺癌,任何死亡率结果均未发现性别差异。因此,与男性相比,接受食管癌根治性切除术的女性食管鳞状细胞癌患者的预后似乎更好,尤其是那些肿瘤分期较早的患者,而食管腺癌患者的预后无性别差异。